SLC31A1 and breast carcinoma: In an experiment targeting human breast cancer cells MCF‐7, SLC31A1 silencing significantly eliminated CoCl2‐induced E‐cadherin downregulation and vimentin up‐regulation, which inhibited tumor progression by inhibiting CoCl2‐induced cytoskeleton rearrangement and EMT marker genes expression [8].